



DEBORAH ANN HALL

Curriculum Vitae

ADDRESS

Department of Neurology
Campus Box B183
4200 East Ninth Avenue
Denver, Colorado 80262
(303) 315-6456 (fax 7583)
Deborah.Hall@uchsc.edu

EDUCATION

Undergraduate: Indiana University 1991-1995, Biology & Chemistry
Medical School: Indiana University 1995-1999, M.D.
Internship: University of Colorado 1999-2000, Internal Medicine
Residency: University of Colorado 2000-2003, Neurology
Fellowship: University of Colorado 2003-2005, Movement Disorders;
American Academy of Neurology 2003-2005, Clinical Research
Graduate: University of Colorado 2003-2004, Certificate in Clinical Science;
University of Colorado 2004-current, Ph.D. candidate in Clinical
Investigation

PROFESSIONAL POSITIONS

1997-1999 Senior Extern, Emergency Medicine, St. Francis Hospital, Beechgrove,
Indiana
1999-2000 Medical Internship, Internal Medicine, University of Colorado Health
Sciences
2000-2003 Neurology Residency, University of Colorado Health Sciences
2002-2003 Chief Resident, Neurology, University of Colorado Health Sciences
2003-2005 Instructor/Fellow, Movement Disorders Division, Neurology,
University of Colorado Health Sciences Center
2005-present Instructor (Faculty position), Neurology, University of Colorado Health
Sciences Center
2003-present Clinical Instructor, Neurology, Veterans Administration Hospital,
Denver
2003-present Clinical Instructor, Neurology, The Children's Hospital, Denver

LICENSURE & CERTIFICATION

8/2001 M.D. Colorado license #39840

9/2004 Specialty Certification in Neurology, #52905, American Board of Neurology and Psychiatry

EXPERIENCE AND PROFESSIONAL MEMBERSHIPS

1993-1995 Director, Indiana University Student Association
1996-1997 Vice President, American Women's Medical Association, Indiana University
1997 Student Coordinator, Moi University School of Medicine, Eldoret, Kenya
1997-1998 HIV/AIDS Educator, Community Outreach Program, Indiana
1997-1998 Member, International Health and Medical Education Consortium
1999 Neurology Clerkship, Institute of Neurology, Queensquare, London, England
1998-1999 Vice President, Indiana University School of Medicine Class of 1999
2000-present Member, American Academy of Neurology
2000-present Member, Executive Committee of the Housestaff Association of University of Colorado
2001-2002 Member, Affiliated Hospitals Committee, University of Colorado
2001-2002 President, Housestaff Association of University of Colorado Health Sciences
2001-2002 Member, Graduate Medical Education Committee, University of Colorado
2002-2003 Member, Trust Advisory Board University of Colorado Health Sciences
2003-present Member, Colorado Society of Clinical Neurologists
2003-present Member, Movement Disorders Society
2004-present Diplomate, American Board of Psychiatry and Neurology

HONORS

1997 Indiana University Graduate Student Organization Educational Enhancement Grant
1999 Indiana University School of Medicine Memorial Fellowship
2003-2005 American Academy of Neurology Clinical Research Training Fellowship
2003-2005 NIH Loan Repayment Program for Clinical Researchers Recipient
2006 Clinical Science Outstanding Ph.D. Student Award, University of Colorado

AD HOC REVIEWER

Movement Disorders, Brain

TEACHING

1. Instructor, Neurology residency training program, 2003 -present
2. "Molecular basis of Huntington's disease" (PhD and masters students) 2004, 2006
3. "Pharmacologic treatment of Parkinson's disease" (medical students) 2004, 2006
4. "Phenomenology of movement disorders" (neurology residents) 2004, 2005, 2006
5. "Parkinson's disease and other movement disorders" (medical students) 2005, 2006
6. "Overview of movement disorders" (physician assistant students) 2004, 2005

7. "Parkinson's disease" (Preventive medicine and rehab residents) 2005
8. Preceptor, Brooke Gustafson, medical student, University of Colorado, 2005
9. "Movement Disorders" (Second year medical students), 2006
10. "Atypical Parkinsonian Disorders" (neurology residents), 2006

INVITED LECTURES

- "Restless Legs Syndrome", Movement Disorder Symposium, Denver, Colorado, 2005
 "Parkinson Disease", Grand Rounds, University of South Dakota, Sioux Falls, 2006
 "Non-motor manifestations of Parkinson disease", Boulder PD Support Group, 2006

PUBLICATIONS

1. Mueller (Hall) D, Gilden D. Brown-Sequard syndrome after esophageal sclerotherapy and crack cocaine abuse. *Neurology* 2002; 1129-1130.
2. Hall DA, Anderson CA, Filley CM, Newcombe J, Hughes RL. A French accent after corpus callosum infarct. *Neurology* 2003;60:1551.
3. Hall DA, Ringel SP. Adult nonketotic hyperglycinemia (NKH) crisis presenting as severe chorea and encephalopathy. *Mov Disord* 2003;DOI 10.1002/mds.10681.
4. Jacquemont S, Hagerman RJ, Leehey MA, **Hall DA**, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. *JAMA* 2004;291:460-469.
5. Jacquemont S, Farzin F, **Hall DA**, et al. Aging in individuals with the *FMR1* mutation. *AJMR* 2004; 109:154-64.
6. Pelak VS, Hall DA. Neuro-ophthalmic manifestations of neurodegenerative disease. *Ophth clinics of NA* 2004;17:311-320.
7. Hall DA, Leehey MA, Filley CM, Steinbert E, Montine TJ, Schellenberg G, Bosque P, Nixon R, Bird TD. *PRNP* H187R mutation associated with neuropsychiatric disorders in childhood and dementia. *Neurology* 2005;64:1304-1306.
8. Hall DA, Berry-Kravis E, Jacquemont S, Rice CD, Cogswell J, Zhang L, Hagerman R, Hagerman PJ, Leehey MA. Prior diagnosis given to persons with the Fragile X-associated tremor/ataxia syndrome. *Neurology* 2005;65:299-301.
9. Hessler D, Tassone F, Loesch DZ, Berry-Kravis E, Leehey MA, Gane LW, Barbato I, Rice C, Gould E, **Hall DA**, et al. Abnormal elevation of *FMR1* mRNA is associated with psychological symptoms in individuals with the fragile X premutation. *Am J Med Genet B Neuropsychiatr Genet.* 2005 Nov 5;139(1):115-21.
10. Hall DA, Hagerman RJ, Hagerman PJ, Jacquemont S, Leehey MA. Prevalence of *FMR1* repeat expansions in movement disorders: a systematic review. *Neuroepidemiology* 2006;26:151-155.
11. Hall DA, Berry-Kravis E, Hagerman RJ, Hagerman PJ, Rice CD, Leehey MA. Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome (FXTAS). *Movement Disorders, in press.*
12. Hall DA, Wadwa RP, Goldenberg NA, Norris J. Maternal cardiovascular risk factors for term neonatal seizures: a population-based study in Colorado 1989-2003. *J Child Neurology, in press.*

ABSTRACTS/POSTER PRESENTATIONS

1. "Primary Care in Mosoriat, Kenya", International Health and Medical Education Consortium International Conference, Chicago, Illinois, 1997 (poster).
2. Hall DA, Anderson CA, Filley CM, Newcombe J, Hughes RL. Foreign accent syndrome following a stroke in the corpus callosum. *J of Neurol, Neurosurg, Psychiat* 2002;72.
3. Smith DB, Anderson CA, Hall DA, Hughes RL, Stambuk M. EScenario: A preliminary evaluation. American Academy of Neurology Annual Meeting, April 2003.
4. Hall DA, Leehey MA, Schellenberg GD, Filley C, Bird T. Maternally inherited early-onset dementia with extrapyramidal features, ataxia, and anticipation. *Neurology* 2003;60:P06.035.
5. "Neurogenic weakness, ataxia, neuropathy, ophthalmoplegia, and stroke-like episodes", the Walsh Session of the North American Neuro-Ophthalmology Society Meeting, Orlando, Florida 2004 (presentation).
6. Hall DA, Leehey MA, Schellenberg GD, Filley C, Bird T. A prion protein gene mutation H187R in a family with early-onset dementia and neuropsychiatric disorders in childhood and adolescence. *Neurology* 2004;62:Po5.126..
7. Hagerman PJ, Jacquemont S, Hagerman R, Leehey MA, Hall DA, Levine R, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome (FXTAS) in a premutation carrier population: initial results from a California family-based study. *Neurology* 2004;62:P02.066.
8. Hall DA, Pelak VS, Hagerman RJ, Hagerman PJ, Leehey MA. Ocular motility in fragile X premutation carriers and fragile X-associated tremor/ataxia syndrome (FXTAS). *Movement Disord* 2004;19:P9.
9. Leehey MA, Berry-Kravis E, Jacquemont J, Zhang L, Hagerman R, Hagerman PJ. Misdiagnosis of fragile X-associated tremor/ataxia syndrome (FXTAS). *Movement Disord* 2004;19:P985.
10. Hall DA, Rice CD, Hagerman RR, Hagerman PJ, Berry-Kravis E, Leehey MA. Medical treatment for the fragile X-associated tremor/ataxia syndrome. *Movement Disord* 2004;19:1127.
11. Leehey MA, Hall DA, Rice C, Jacquemont S, Zhang L, Grigsby J, Hagerman PJ, Hagerman RR. The clinical course of fragile-X associated tremor/ataxia syndrome (FXTAS). *Movement Disord* 2005;19:1122.
12. Hall DA, Parsons J, Leehey MA, Benke T. Paroxysmal nonkinesigenic dyskinesia responsive to a gluten-free diet. *Movement Disord* 2005;20:S57.
13. Agarwal P, Seeberger L, Hall DA, Segro V. Acute and tardive dyskinesias induced by aripiprazole. *Movement Disord* 2005;19:S14.
14. Leehey MA, Hall DA, Rice C, Jacquemont S, Zhang L, Grigsby J, Hagerman R, Hagerman PJ. Preliminary study of the natural history of the fragile X associated tremor/ataxia syndrome (FXTAS). *Neurol* 2005;64:A93.
15. Hall DA, J Sheeder, M Efird, D Smith, C Wells, T Box, AL Shroyer. Clinical Science Research Program : the Missing Mentor. *J Invest Med* 2006;54(1).

16. Arciniegas DB, Frey KL, Rojas DC, Kozora E, **Hall DA**, Anderson CA. Long-term neurobehavioral and functional outcome following neuroinvasive West Nile Virus infection. *J Neuropsychiatry Clin Neurosci* 2006;18:256-285.

RESEARCH STUDIES

1 K23 NS052487-01

4/1/06-3/30/11

NINDS

PI: Hall D

Prevalence of FMR1 Expansions in Movement Disorders

The aim of this study is to use regression models to determine the prevalence of FMR1 repeat expansions in patients with tremor, ataxia, and parkinsonism. In addition, it provides protected time for career development.

American Academy of Neurology Clinical Research Fellowship 7/1/03-6/30/05

PI: Hall D

Study of Medications for Treatment of Neurological Symptoms Associated with the fragile X premutation

This study will provide preliminary information regarding interventions for symptoms secondary to the fragile X associated tremor ataxia syndrome (FXTAS). The award also provided protected time for didactic coursework in clinical research methodology.

NIH Loan Repayment Program

7/1/03-6/30/06

Clinical Research

PI: Hall D

This funding is provided for conducting clinical research, involving direct interaction with human subjects, at least 50 percent of the recipient's time. The research is focused on FXTAS and movement disorders and involves investigation of the treatments and causes of these diseases.

Role: Recipient

1 RO1 NS044299-01

9/15/03-6/31/08

NIH/NINDS

PI: Grigsby J

Action Tremor and Dementia in Male Carriers of Fragile X

The goal of this project is to investigate the neuropsychological and imaging features of affected *FMR1* premutation carriers.

Role: Consultant

RFA-NS-02-00

7/1/02-6/31/06

NIH

PI: Hagerman PJ

Neurological Phenotype of FMR1 Premutation Carriers

The major goals of this project are to define the neurological phenotype of affected premutation carriers. This project involves three centers. Dr. Leehey is the PI at the University of Colorado site.

Role: Consultant

1 RO1 HD043770-01

4/11/03-3/31/08

NIH

PI: Schenkman M

Exercise, Physical Function, and Parkinson's Disease

The purpose of this study is determine if an intervention targeting specific impairments of spinal flexibility and function associated with Parkinson's disease confers greater benefit than a general conditioning program.

Role: Consultant

1 R01 CI000224-01

9/01/04 – 8/31/06

NIH/CDC

PI: Arciniegas, D

West Nile Virus: Neurobehavioral and Functional Outcome

A prospective study of the consequences of neuroinvasive West Nile virus infections. The study will focus on individuals with West Nile encephalitis admitted for acute rehabilitation and will evaluate both the types and severity of neurobehavioral and functional impairments in this population as well as the change in those impairments during the first year after infection.

Role: Consultant

U10/CCU925123-01

9/30/05 - 9/29/06

CDC

PI: Hagerman, R.J.

Fragile X Syndrome Cascade Testing and Genetic Counseling Protocols

This grant will allow UC Davis, several consultants, and parents and patients to develop protocols for cascade testing and genetic counseling in fragile X, through a series of focused advisory meetings.

Role: Consultant

NINDS PD Cooperative Studies

7/1/03-1/01/05

The objective will assess the impact of minocycline and creatine on the progression of PD in order to assess whether it is non-futile to proceed with further study of these agents.

Role: Co-investigator

Boehringer Ingelheim

7/1/04-6/29/05

Pramipexole in Restless Legs Syndrome

The goal is determine the safety and efficacy of pramipexole in the treatment of restless legs syndrome.

Role: Sub-investigator

Biogen

7/1/05-7/1/08

CombiRx

A multi-center double-blind randomized study comparing the combined use of interferon beta-1a & glatiramer acetate to either agent alone in patients with RR-MS.
Role: Consultant